Skip to main content
. Author manuscript; available in PMC: 2020 Jun 29.
Published in final edited form as: J Immunother. 2010 May;33(4):435–441. doi: 10.1097/CJI.0b013e3181d32f01

FIGURE 3.

FIGURE 3.

Regression curves (solid line) (with 95% confidence interval) (dotted line) according to the number of tumor-infiltrating lymphocytes positive for the expression of FoxP3. Panels compare overall survival (A), relative overall survival (from trial enrolment to death; B), and progression-free survival (C) with the actual number of tumor-infiltrating lymphocytes positive for the expression of FoxP3. Panels compare overall survival (D), relative overall survival (E), and progression-free survival (F) with the actual number of tumor-infiltrating lymphocytes positive for the expression of FoxP3 in patients with (●) or without events (○).